RT Journal Article
T1 Evaluation of Safety, Patient Perception and Efficacy of a New Cymenol-Based Mouth Rinse Formulation: A Randomized Clinical Trial
A1 Araoz González, Ana
A1 Figuero Ruiz, Elena
A1 Serrano, Jorge
A1 Roldán, Silvia
A1 Alonso Álvarez, Bettina María
A1 Sanz Alonso, Mariano
A1 Herrera González, David
AB The aim of this study was to evaluate a newly formulated mouth rinse containing cymenol in patients undergoing supportive periodontal care in terms of safety (primary outcome) and the impact on dental biofilm and gingival inflammation (secondary outcomes). This research was designed as a pilot, controlled, randomized, parallel, triple-blinded, single-center, clinical trial of a 12-week duration. Adverse events and product perception were assessed by a questionnaire. Clinical, patient-reported outcomes (PROs), compliance, tooth staining, dentin hypersensitivity and microbiological variables were also evaluated. Student T, Mann–Whitney-U and Chi-square tests were applied. Thirty participants (15 per group) were included, randomized and followed for 12 weeks. No adverse events were reported. The questionnaire showed an overall rating of 7.2 (out of 10) in the experimental group and of 8.2 in the control group (p = 0.165) at 12 weeks. No statistically significant differences were observed in terms of gingival health, tooth staining, dentin hypersensitivity or microbiological outcomes between groups at baseline, 6- and 12-week visits. The adjuvant use of the new mouth rinse formulation proved to be as safe as the control product and no significant differences were observed in terms of clinical efficacy.
PB MDPI
YR 2024
FD 2024-07-28
LK https://hdl.handle.net/20.500.14352/113667
UL https://hdl.handle.net/20.500.14352/113667
LA eng
NO Araoz A, Figuero E, Serrano J, Roldán S, Alonso B, Sanz M, Herrera D. Evaluation of Safety, Patient Perception and Efficacy of a New Cymenol-Based Mouth Rinse Formulation: a Randomized Clinical Trial. Applied Sciences. 2024; 14(15):6595. https://doi.org/10.3390/app14156595
DS Docta Complutense
RD 8 abr 2025